ANACOR PHARMACEUTICALS INC COM
ANAC
ANAC was delisted on the 23rd of June, 2016.
199 hedge funds and large institutions have $2.48B invested in ANACOR PHARMACEUTICALS INC COM in 2016 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 74 increasing their positions, 63 reducing their positions, and 54 closing their positions.
69% more call options, than puts
Call options by funds: $114M | Put options by funds: $67.4M
17% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 63
7% less funds holding
Funds holding: 214 → 199 (-15)
28% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 54
38% less funds holding in top 10
Funds holding in top 10: 8 → 5 (-3)
49% less capital invested
Capital invested by funds: $4.84B → $2.48B (-$2.36B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$86.9M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$68.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$59.3M |
| 4 |
YCMGA
York Capital Management Global Advisors
New York
|
+$34.3M |
| 5 |
UIM
USS Investment Management
London,
United Kingdom
|
+$27.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
-$45.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$29.8M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$24.1M |
| 4 |
CCI
Columbus Circle Investors
|
-$22.3M |
| 5 |
Two Sigma Advisers
New York
|
-$18.5M |
ANAC Hedge Fund Activity: Q1 2016 in Review
199 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in ANACOR PHARMACEUTICALS INC COM (ANAC) for Q1 2016, worth a combined $2.48B — down 49% from $4.84B a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of ANAC and 39 opened new positions — a net loss of 15 holders — while 63 trimmed existing stakes and 74 added.
The largest buyer was Goldman Sachs, adding an estimated $86.9M. The largest seller was Westfield Capital Management, exiting entirely with an estimated $45.9M sold.
- 199 institutional investors held ANACOR PHARMACEUTICALS INC COM (ANAC) as of Q1 2016, down from 214 in Q4 2015.
- Funds reported $2.48B of ANACOR PHARMACEUTICALS INC COM stock for Q1 2016, down 49% quarter-over-quarter.
- 39 funds opened new ANACOR PHARMACEUTICALS INC COM positions in Q1 2016 and 54 closed out, a net change of -15 holders.
- The largest ANACOR PHARMACEUTICALS INC COM buyer in Q1 2016 was Goldman Sachs, an estimated $86.9M added.
- The largest ANACOR PHARMACEUTICALS INC COM seller in Q1 2016 was Westfield Capital Management, an estimated $45.9M sold.
Based on aggregated 13F filings for Q1 2016.